PDF(Pubmed)
Abstract：
Managing inflammatory bowel disease (IBD) is becoming increasingly complex and personalized, considering the advent of new advanced therapies with distinct mechanisms of action. Achieving mucosal healing (MH) is a pivotal therapeutic goal in IBD management and can prevent IBD progression and reduce flares, hospitalization, surgery, intestinal damage, and colorectal cancer. Employing proactive disease and therapy assessment is essential to achieve better control of intestinal inflammation, even if subclinical, to alter the natural course of IBD. Periodic monitoring of fecal calprotectin (FC) levels and interval endoscopic evaluations are cornerstones for evaluating response/remission to advanced therapies targeting IBD, assessing MH, and detecting subclinical recurrence. Here, we comment on the article by Ishida et al Moreover, this editorial aimed to review the role of FC and endoscopic scores in predicting MH in patients with IBD. Furthermore, we intend to present some evidence on the role of these markers in future targets, such as histological and transmural healing. Additional prospective multicenter studies with a stricter MH criterion, standardized endoscopic and histopathological analyses, and virtual chromoscopy, potentially including artificial intelligence and other biomarkers, are desired.
摘要：
管理炎症性肠病（IBD）变得越来越复杂和个性化，考虑到具有不同作用机制的新的先进疗法的出现。实现粘膜愈合（MH）是IBD管理的关键治疗目标，可以防止IBD进展和减少耀斑，住院治疗,手术,肠道损伤,还有结直肠癌.采用主动的疾病和治疗评估对于更好地控制肠道炎症至关重要。即使亚临床，改变IBD的自然病程。定期监测粪便钙卫蛋白（FC）水平和间隔内镜评估是评估针对IBD的晚期治疗的反应/缓解的基石。评估MH，并检测亚临床复发。这里,我们评论石田等人的文章，这篇社论旨在回顾FC和内镜评分在预测IBD患者MH中的作用.此外，我们打算提供一些关于这些标记在未来目标中的作用的证据，如组织学和透壁愈合。具有更严格MH标准的其他前瞻性多中心研究，标准化内镜和组织病理学分析，和虚拟显色，可能包括人工智能和其他生物标志物，是渴望的。
